Binimetinib for the treatment of NRAS-mutant melanoma

Paola Queirolo, Francesco Spagnolo

Research output: Contribution to journalArticlepeer-review


Introduction: Activating NRAS mutations occur in approximately 15–20% of melanomas and are the second most common oncogenic driver mutation in this disease, after BRAF mutations. There is an unmet medical need for new targeted therapy opportunities in metastatic patients whose tumors harbor an NRAS mutation. Binimetinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, has shown clinical activity in this group of patients. Areas covered: The purpose of this paper was to review the safety, activity and efficacy of the MEK inhibitor binimetinib for the treatment of NRAS-mutant melanoma, as well as to discuss future therapeutic perspectives such as multiple pathways, targeted therapy, and combinations with immunotherapy. Expert commentary: Only a modest progression-free survival (PFS) benefit was observed in NRAS-mutated patients who received binimetinib compared with dacarbazine in a randomized phase 3 clinical trial, with no improvement in overall survival. Nevertheless, binimetinib represents another promising treatment option for advanced melanoma and the first molecularly targeted therapy for the NRAS-mutant population. Binimetinib may also have a role in treating NRAS-mutated melanoma patients after failure of immunotherapy.

Original languageEnglish
Pages (from-to)985-990
Number of pages6
JournalExpert Review of Anticancer Therapy
Issue number11
Publication statusPublished - Nov 2 2017


  • binimetinib
  • MEK
  • MEK162
  • Melanoma
  • NRAS
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Binimetinib for the treatment of NRAS-mutant melanoma'. Together they form a unique fingerprint.

Cite this